ЧАСТНЫЕ ВОПРОСЫ ПАТОГЕНЕЗА ВОСПАЛИТЕЛЬНЫХ ЗАБОЛЕВАНИЙ КИШЕЧНИКА
Аннотация
Об авторах
А. М. ПершкоРоссия
В. Б. Гриневич
Россия
И. А. Соловьев
Россия
А. В. Шотик
Россия
Д. П. Курило
Россия
Список литературы
1. Белоусова Е. А. Язвенный колит и болезнь Крона. - Тверь: Издательство «Триада», 2002. - 128 с
2. Джонкерс Д., Пендерс Д., Маскли А., Пьерик М. Пробиотики в лечении воспалительных заболеваний кишечника (систематических обзор интервенционных исследований среди взрослых пациентов). Гастроэнтерология и гепатология, 2013, № 2, С. 28-48
3. Маев И.В., Андреев Д. Н., Дичева Д. Т., Великанов Е. В. Болезнь Крона: этиопатогенез, диагностика и консервативное лечение.//Пособие для врачей. - Москва, 2016. - 67с
4. Kirsner JB, Spencer JA. Family occurrences of ulcerative colitis, regional enteritis, and ileocolitis. // Ann. Intern. Med. - 1963. - vol. 59. - pp.133-144
5. Hugot J-P, Laurent-Puig P, Gower-Rousseau C et al. Mapping of a susceptibility locus for Crohn’s disease on chromosome 16. Nature, 1996, vol. 379, pp. 821-823.
6. Cooney R., Baker J., Brain O et al. Nod2 stimulation induces autophagy in dendritic cells influencing bacterial handling and antigen presention. Nat. Med, 2010, vol.16, pp.90-97.
7. Hooper K., Barlou P., Stevens C., Henderson P. Inflammatory bowel disease drugs: a focus on autophagy. Jornal of Crohn’s and Colitis, 2017, vol.11, № 1, pp. 118-127.
8. Ogura Y., Bonen D. K., Inohara N. et al. A frameshift mutation in Nod2 associated with susceptibility to Crohn’s desease. Nature, 2001, vol.411, pp. 603-606.
9. Hugot J-P, Chamaiilard M., Zouali H. et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn’s disease. Nature, 2001, vol.411, pp. 599-603.
10. Сhassaing B., Vijay-Kumar M., Gewitz A. T. How diet can impact gut microbiota to promote or endanger health. Curr. Opin.Gastroenterolog, 2017, vol.33, № 6, pp. 417-421.
11. Duerr R. H., Taylor K. D., Brant S. R. et al. A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science, 2006, vol. 314, pp. 1461-1463.
12. Kitahora T, Utsunomiya T, Yokota A. Epidemiological study of ulcerative colitis in Japan: incidence and familial occurrence. The Epidemiology Group of the Research Committee of Inflammatory Bowel Disease in Japan. J. Gastroentero, 1995, vol. 30 (Suppl. 8), pp. 5-8.
13. Fiocchi С. Inflammatory bowel disease pathogenesis: Where are we? J. Gastroenter. Hepatol, 2015, vol. 30 (Suppl. 1), pp. 12-18.
14. Brown A., Rampertab C., Mullin G. E. Existing Dietary Guidelines for Crohn’s Disease and Ulcerative Colitis. Expert Rev. Gastroenterol. Hepatol, 2011, vol.5, № 3, pp. 411-425.
15. Wu G. D., Chen J., Hoffmann C. et al. Linking long-term dietary patterns with gut microbial enterotypes. Science, 2011, vol. 334, pp. 105-108.
16. Desai M.S, Seekatz A.M, Koropatkin N. M., et al. A dietary fiber-deprived gut microbiota degrades the colonic mucus barrier and enhances pathogen susceptibility. Cell, 2016, vol, 167, pp.1339-1353.
17. Hamer H. M., Jonkers D., Venema K. et al. Review article: the role of butyrate on colonic function. Aliment. Pharmacol.Ther, 2008, vol.27, pp. 833-839.
18. Park J, Kim M, Kang S.G, et al. Short-chain fatty acids induce both effector and regulatory T cells by suppression of histone deacetylases and regulation of the mTOR-S6K pathway. Mucosal Immunol, 2015, vol.8, pp.80-93.
19. Rambaud Y.C, Buts Y. P., Corthier G., Flourie B. Gut microflora. Digestive physiology and pathology. - Paris, 2006.
20. Маев И. В., Андреев Д. Н., Дичева Д. Т., Великанов Е. В. Болезнь Крона: этиопатогенез, диагностика и консервативное лечение.//Пособие для врачей. - Москва, 2016. - 67с.
21. Salazar N., Dewulf E. M., Neyrinck A. M., et al. Inulin-type fructans modulate intestinal bifidobacterium species populations and decrease fecal short-chain fatty acids in obese women. ClinNutr, 2015, vol.34, pp. 501-507.
22. Swidsinski A., Ung V., Sydora B.C, et al. Bacterial overgrowth and inflammation of small intestine after carboxymethylcellulose ingestion in genetically susceptible mice. Inflamm. Bowel Dis, 2009, vol.15, pp.359-364.
23. Chassaing B., Van de Wiele T., De Bodt J., et al. Dietary emulsifiers directly alter human microbiota composition and gene expression ex vivo potentiating intestinal inflammation. Gut, 2017, vol. 66, pp. 1414-1427.
24. Roberts C. L., Keita A. V., Duncan S. H., et al. Translocation of Crohn›s disease Escherichia coliacross M-cells: contrasting effects of soluble plant fibres and emulsifiers. Gut, 2010, vol. 59, pp.1331-1339.
25. Chassaing B., Koren O., Goodrich J. K., et al. Dietary emulsifiers impact the mouse gut microbiota promoting colitis and metabolic syndrome. Nature, 2015, vol. 519, pp.92-96.
26. Yan X., Huang Y., Wang H. et al. Maternal obesity induces sustained inflammation in both fetal and offspring large intestine of sheep. Inflamm. Bowel Dis, 2011, vol. 17, pp. 1513-22.
27. Gonzalez-Correa C.A., Mulett-Vásquez E., Miranda D. A., et al. The colon revisited or the key to wellness, health and disease. Medical Hypotheses, 2017, Vol. 108, p.133.
28. Chassaing B., Koren O., Carvalho F. A., et al. AIEC pathobiont instigates chronic colitis in susceptible hosts by altering microbiota composition. Gut, 2013, vol. 63, pp.1069-1080.
29. Chassaing B., Raja S. M., Lewis J. D., et al. Colonic microbiota encroachment correlates with dysglycemia in humans. Cell MolGastroenterolHepatol, 2017, vol. 4, pp. 205-221.
30. Faith J. J., Guruge J. L., Charbonneau M., et al. The long-term stability of the human gut microbiota. Science, 2013, vol. 341, p.1237439.
31. Human Microbiome Project Collaboration Structure, function and diversity of the healthy human microbiome. Nature, 2012, vol. 486, pp.207-214.
32. Kostic A. D., Gevers D., Siljander H., et al. The dynamics of the human infant gut microbiome in development and in progression toward type 1 diabetes. Cell Host Microbe, 2015, vol.17, pp.260-273.
33. Lloyd-Price J, Abu-Ali G, Huttenhower C. The healthy human microbiome. Genome Med, 2016, vol. 8, p.51.
34. Qin J, Li R, Raes J, et al. A human gut microbial gene catalogue established bymetagenomic sequencing. Nature, 2010, vol. 464, pp.59-65.
35. Butto L.F, Haller D. Dysbiosis in intestinal inflammation: cause or consequence. Int. J. Med. Microbiol, 2016, vol. 306, pp. 302-309.
36. Wu G.D, Compher C, Chen E.Z, et al. Comparative metabolomics in vegans and omnivores reveal constraints on diet-dependent gut microbiota metabolite production. Gut, 2014, vol. 65, pp.63-72.
37. Hildebrandt M.A, Hoffmann C, Sherrill-Mix S.A, et al. High-fat diet determines the composition of the murine gut microbiome independently of obesity. Gastroenterology, 2009, vol.137, pp.1716-1724.
38. Filippo C, Cavalieri D, Di Paola M et al. Impact of diet in shaping gut microbiota revealed by a comparative study in children from Europe and rural Africa. Proc. Natl Acad. Sci, 2010, vol.107, pp. 14691-14696.
39. Devkota S, Wang Y, Musch M.W et al. Dietary-fat-induced taurocholic acid promotes pathobiont expansion and colitis in Il 10- mice. Nature, 2012, vol. 487, pp. 104-108.
40. Chen Y., Blaser M. J. Helicobacter pylori colonization is inversely assosiated with childhood asthma. J. Infect. Dis, 2008, vol. 198, pp.553-560.
41. Luther J., Dave M., Higgins R. et al. Association between Helicobacter pillory and inflammatory bowel disease: a meta- analysis and systematic review of the literature. Inflam. Bow.Dis, 2010, vol.16, pp.1077-1084.
42. Luther J., Stephanie Y., Owyang Y. et al. Helicobacter pylori DNA decreases pro-inflammotory cytokine production by dendritic cells and attenuates dextran sulphate-induced cjlitis. Gut, 2011, vol.60, № 11, pp.1479-1486.
43. Джонкерс Д., Пендерс Д., Маскли А., Пьерик М. Пробиотики в лечении воспалительных заболеваний кишечника (систематических обзор интервенционных исследований среди взрослых пациентов). Гастроэнтерология и гепатология, 2013, № 2, С. 28-48.
44. Borchers A. T., Selmi C., Meyers F. J. et al. Probiotics and immunity. Gastroenterol, 2009, vol. 44, № 1, pp. 26-46
45. Пилипенко В. И. Пробиотики как сигнальные молекулы: Saccharomycesboulardii. Клиническая гастроэнтерология и гепатология, 2008, Т. 1,№ 6, С. 456-462
46. Oeschlaeger T. A. Mechanisms of probiotic actions: a review. Int. J. Med. Microbiol, 2010, vol.300, № 1, pp. 57-62.
47. Karczewski J., Troost F. J., Konings I. et al. Regulation of human epithelial tight junction proteins by Lactobacillus plantarum in vivo and protective effects on the epithelial barrier. Am. J. Physiol. Gastrointest, 2010, vol.298, № 6, pp. G851-G859.
48. Mattar A. F., Teitelbaum D. H., Drongowski R. A. et al. Probiotics up-regulate MUC-2 mucin gene expression in a Caco-2 cell-culture model. Pediatr. Surg. Int, 2002, vol.18, № 7, pp. 586-590.
49. Claes I. J., Keersmaecker S. C., Vanderleyden J. et al. Lessons from probiotic-host interaction stadies in murine models of experimental colitis. Mol. Nutr.Food Res, 2011, vol.55, № 10, pp. 1441-1453.
50. Guslandi M., Mezzi G., Testoni P. A. Saccaromycesboulardimaitenanse treatment of Crohnsdesease. Dig. Dis. Sci, 2000, vol.11, pp.1462-1464.
51. Khalili H., Granath F., Smedby K. E. et al. Association Between Long-term Oral Contraceptive Use and Risk of Crohn’s Disease Complications in a Nationwide Study. Gastroenterology, 2016, vol.150, № 7, pp. 1561-1567.
52. Moayyedi P. Fecal Transplantation: Any Real Hope for Inflammatory Bowel Disease? Curr. Opin.Gastroenterol, 2016, vol. 32, № 4. - pp. 282-286.
Рецензия
Для цитирования:
Першко А.М., Гриневич В.Б., Соловьев И.А., Шотик А.В., Курило Д.П. ЧАСТНЫЕ ВОПРОСЫ ПАТОГЕНЕЗА ВОСПАЛИТЕЛЬНЫХ ЗАБОЛЕВАНИЙ КИШЕЧНИКА. Экспериментальная и клиническая гастроэнтерология. 2018;(5):140-149.
For citation:
Pershko A.M., Grinevich V.B., Solovyov I.A., Shotik A.V., Kurilo D.P. PRIVATE THE PATHOGENESIS OF INFLAMMATORY BOWEL DISEASES. Experimental and Clinical Gastroenterology. 2018;(5):140-149. (In Russ.)